Chapter 21 Interleukin-6 and Insulin Resistance

Jeong Ho Kim, Rebecca A. Bachmann, Jie Chen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic low-grade inflammation has been well recognized as a key feature of obesity that is correlated with insulin resistance and type 2 diabetes. Among the adipose-secreted factors (adipokines), the inflammatory regulator interleukin-6 (IL-6) has emerged as one of the potential mediators that link obesity-derived chronic inflammation with insulin resistance. Adipose tissue contributes to up to 35% of circulating IL-6, the systemic effects of which have been best demonstrated in the liver, where a STAT3-SOCS-3 pathway mediates IL-6 impairment of insulin actions. However, this cytokine displays pleiotropic functions in a tissue-specific and physiological context-dependent manner. In contrast to its role in liver, IL-6 is believed to be beneficial for insulin-regulated glucose metabolism in muscle. Furthermore, the effects of the cytokine are seemingly influenced by whether it is present acutely or chronically; the latter is the setting associated with insulin resistance. Herein we review the in vivo and in vitro studies that have examined the role of IL-6 in insulin signaling and glucose metabolism in the insulin target tissues: liver, adipose, and skeletal muscle.

Original languageEnglish (US)
Title of host publicationVitamins and Hormones
Pages613-633
Number of pages21
EditionC
DOIs
StatePublished - Mar 5 2009

Publication series

NameVitamins and Hormones
NumberC
Volume80
ISSN (Print)0083-6729

Fingerprint

Insulin Resistance
Interleukin-6
Insulin
Adipose Tissue
Liver
Obesity
Cytokines
Inflammation
Glucose
Adipokines
Type 2 Diabetes Mellitus
Skeletal Muscle
Muscles

Keywords

  • Adipose
  • Chronic inflammation
  • GLUT4
  • IL-6
  • Liver
  • SOCS
  • STAT
  • Skeletal muscle
  • insulin resistance

ASJC Scopus subject areas

  • Physiology
  • Endocrinology

Cite this

Kim, J. H., Bachmann, R. A., & Chen, J. (2009). Chapter 21 Interleukin-6 and Insulin Resistance. In Vitamins and Hormones (C ed., pp. 613-633). (Vitamins and Hormones; Vol. 80, No. C). https://doi.org/10.1016/S0083-6729(08)00621-3

Chapter 21 Interleukin-6 and Insulin Resistance. / Kim, Jeong Ho; Bachmann, Rebecca A.; Chen, Jie.

Vitamins and Hormones. C. ed. 2009. p. 613-633 (Vitamins and Hormones; Vol. 80, No. C).

Research output: Chapter in Book/Report/Conference proceedingChapter

Kim, JH, Bachmann, RA & Chen, J 2009, Chapter 21 Interleukin-6 and Insulin Resistance. in Vitamins and Hormones. C edn, Vitamins and Hormones, no. C, vol. 80, pp. 613-633. https://doi.org/10.1016/S0083-6729(08)00621-3
Kim JH, Bachmann RA, Chen J. Chapter 21 Interleukin-6 and Insulin Resistance. In Vitamins and Hormones. C ed. 2009. p. 613-633. (Vitamins and Hormones; C). https://doi.org/10.1016/S0083-6729(08)00621-3
Kim, Jeong Ho ; Bachmann, Rebecca A. ; Chen, Jie. / Chapter 21 Interleukin-6 and Insulin Resistance. Vitamins and Hormones. C. ed. 2009. pp. 613-633 (Vitamins and Hormones; C).
@inbook{f115d4774d614ef9a580afa05296fe86,
title = "Chapter 21 Interleukin-6 and Insulin Resistance",
abstract = "Chronic low-grade inflammation has been well recognized as a key feature of obesity that is correlated with insulin resistance and type 2 diabetes. Among the adipose-secreted factors (adipokines), the inflammatory regulator interleukin-6 (IL-6) has emerged as one of the potential mediators that link obesity-derived chronic inflammation with insulin resistance. Adipose tissue contributes to up to 35{\%} of circulating IL-6, the systemic effects of which have been best demonstrated in the liver, where a STAT3-SOCS-3 pathway mediates IL-6 impairment of insulin actions. However, this cytokine displays pleiotropic functions in a tissue-specific and physiological context-dependent manner. In contrast to its role in liver, IL-6 is believed to be beneficial for insulin-regulated glucose metabolism in muscle. Furthermore, the effects of the cytokine are seemingly influenced by whether it is present acutely or chronically; the latter is the setting associated with insulin resistance. Herein we review the in vivo and in vitro studies that have examined the role of IL-6 in insulin signaling and glucose metabolism in the insulin target tissues: liver, adipose, and skeletal muscle.",
keywords = "Adipose, Chronic inflammation, GLUT4, IL-6, Liver, SOCS, STAT, Skeletal muscle, insulin resistance",
author = "Kim, {Jeong Ho} and Bachmann, {Rebecca A.} and Jie Chen",
year = "2009",
month = "3",
day = "5",
doi = "10.1016/S0083-6729(08)00621-3",
language = "English (US)",
isbn = "9780123744081",
series = "Vitamins and Hormones",
number = "C",
pages = "613--633",
booktitle = "Vitamins and Hormones",
edition = "C",

}

TY - CHAP

T1 - Chapter 21 Interleukin-6 and Insulin Resistance

AU - Kim, Jeong Ho

AU - Bachmann, Rebecca A.

AU - Chen, Jie

PY - 2009/3/5

Y1 - 2009/3/5

N2 - Chronic low-grade inflammation has been well recognized as a key feature of obesity that is correlated with insulin resistance and type 2 diabetes. Among the adipose-secreted factors (adipokines), the inflammatory regulator interleukin-6 (IL-6) has emerged as one of the potential mediators that link obesity-derived chronic inflammation with insulin resistance. Adipose tissue contributes to up to 35% of circulating IL-6, the systemic effects of which have been best demonstrated in the liver, where a STAT3-SOCS-3 pathway mediates IL-6 impairment of insulin actions. However, this cytokine displays pleiotropic functions in a tissue-specific and physiological context-dependent manner. In contrast to its role in liver, IL-6 is believed to be beneficial for insulin-regulated glucose metabolism in muscle. Furthermore, the effects of the cytokine are seemingly influenced by whether it is present acutely or chronically; the latter is the setting associated with insulin resistance. Herein we review the in vivo and in vitro studies that have examined the role of IL-6 in insulin signaling and glucose metabolism in the insulin target tissues: liver, adipose, and skeletal muscle.

AB - Chronic low-grade inflammation has been well recognized as a key feature of obesity that is correlated with insulin resistance and type 2 diabetes. Among the adipose-secreted factors (adipokines), the inflammatory regulator interleukin-6 (IL-6) has emerged as one of the potential mediators that link obesity-derived chronic inflammation with insulin resistance. Adipose tissue contributes to up to 35% of circulating IL-6, the systemic effects of which have been best demonstrated in the liver, where a STAT3-SOCS-3 pathway mediates IL-6 impairment of insulin actions. However, this cytokine displays pleiotropic functions in a tissue-specific and physiological context-dependent manner. In contrast to its role in liver, IL-6 is believed to be beneficial for insulin-regulated glucose metabolism in muscle. Furthermore, the effects of the cytokine are seemingly influenced by whether it is present acutely or chronically; the latter is the setting associated with insulin resistance. Herein we review the in vivo and in vitro studies that have examined the role of IL-6 in insulin signaling and glucose metabolism in the insulin target tissues: liver, adipose, and skeletal muscle.

KW - Adipose

KW - Chronic inflammation

KW - GLUT4

KW - IL-6

KW - Liver

KW - SOCS

KW - STAT

KW - Skeletal muscle

KW - insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=61349156849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349156849&partnerID=8YFLogxK

U2 - 10.1016/S0083-6729(08)00621-3

DO - 10.1016/S0083-6729(08)00621-3

M3 - Chapter

C2 - 19251052

AN - SCOPUS:61349156849

SN - 9780123744081

T3 - Vitamins and Hormones

SP - 613

EP - 633

BT - Vitamins and Hormones

ER -